Treasurer Folwell Calls on Novo Nordisk to Lower the Unfair Cost of Weight Loss Drugs
(Raleigh, N.C.) Treasurer Dale R. Folwell, CPA, is calling today for the State Health Plan (Plan) Board of Trustees to end coverage of popular GLP-1 drugs like Wegovy and Saxenda for the purpose of weight loss until the drugs’ manufacturer, Danish multinational Novo Nordisk, prices the drugs fairly.